Literature DB >> 12628711

Transplantation of cells for cardiac repair.

Rutger J Hassink1, Aart Brutel de la Rivière, Christine L Mummery, Pieter A Doevendans.   

Abstract

The inability of adult cardiomyocytes to divide to a significant extent and regenerate the myocardium after injury leads to permanent deficits in the number of functional cells, which can contribute to the development and progression of heart failure. The transplantation of skeletal myoblasts or stem cells or cardiomyocytes derived from them into the injured myocardium is a novel and promising approach in the treatment of cardiac disease and the restoration of myocardial function. In this article, skeletal myoblasts and embryonic and bone marrow stem cells are discussed in the context of their potential therapeutic use in cardiac failure. The state of the art in both laboratory and clinic is presented. We discuss current and intrinsic limitations of cardiac cellular transplantation and suggest directions for future research.

Entities:  

Mesh:

Year:  2003        PMID: 12628711     DOI: 10.1016/s0735-1097(02)02933-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Nitric oxide facilitates cardiomyogenesis in mouse embryonic stem cells.

Authors:  Shinichi Kanno; Peter K M Kim; Karim Sallam; Jing Lei; Timothy R Billiar; Larry L Shears
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-10       Impact factor: 11.205

2.  High-resolution magnetic resonance imaging of iron-labeled myoblasts using a standard 1.5-T clinical scanner.

Authors:  Z Zhang; E J van den Bos; P A Wielopolski; M de Jong-Popijus; D J Duncker; G P Krestin
Journal:  MAGMA       Date:  2004-10-28       Impact factor: 2.310

3.  Morphological characterization of GFP stably transfected adult mesenchymal bone marrow stem cells.

Authors:  Stefania Raimondo; Claudia Penna; Pasquale Pagliaro; Stefano Geuna
Journal:  J Anat       Date:  2006-01       Impact factor: 2.610

4.  The difference between ballistocardiography and stem cells.

Authors:  P A Doevendans; E van Belle
Journal:  Neth Heart J       Date:  2008-09       Impact factor: 2.380

5.  Ischemic cardiac tissue conditioned media induced differentiation of human mesenchymal stem cells into early stage cardiomyocytes.

Authors:  Balasundari Ramesh; Dillip Kumar Bishi; Suneel Rallapalli; Sarasabarathi Arumugam; Kotturathu Mammen Cherian; Soma Guhathakurta
Journal:  Cytotechnology       Date:  2012-03-07       Impact factor: 2.058

6.  Stem cells and ethics: current issues.

Authors:  Jennifer Blair McCormick; Holly A Huso
Journal:  J Cardiovasc Transl Res       Date:  2009-12-01       Impact factor: 4.132

7.  Formation of human myocardium in the rat heart from human embryonic stem cells.

Authors:  Michael A Laflamme; Joseph Gold; Chunhui Xu; Mohammad Hassanipour; Elen Rosler; Shailaja Police; Veronica Muskheli; Charles E Murry
Journal:  Am J Pathol       Date:  2005-09       Impact factor: 4.307

8.  G-CSF enhanced SDF-1 gradient between bone marrow and liver associated with mobilization of peripheral blood CD34+ cells in rats with acute liver failure.

Authors:  Yan Lei; Zhengwen Liu; Qunying Han; Wen Kang; Lei Zhang; Sai Lou
Journal:  Dig Dis Sci       Date:  2009-03-18       Impact factor: 3.199

9.  Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction.

Authors:  Rutger J Hassink; Kishore B Pasumarthi; Hidehiro Nakajima; Michael Rubart; Mark H Soonpaa; Aart Brutel de la Rivière; Pieter A Doevendans; Loren J Field
Journal:  Cardiovasc Res       Date:  2007-12-12       Impact factor: 10.787

10.  Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation.

Authors:  Seyedhossein Aharinejad; Dietmar Abraham; Patrick Paulus; Karin Zins; Michael Hofmann; Wolfgang Michlits; Mariann Gyöngyösi; Karin Macfelda; Trevor Lucas; Karola Trescher; Michael Grimm; E Richard Stanley
Journal:  Cardiovasc Res       Date:  2008-04-23       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.